Answers are grounded in this paper and cite their sources.
MSI-H status and HRD are generally mutually exclusive phenomena across cancer types, but may rarely co-occur, especially in prostate cancer. Although MSI-H samples had a higher BRCAm prevalence relative to microsatellite-stable tumors, these BRCA1/2 mutations were generally monoallelic and were not associated with elevated gLOH. Our findings suggest that most BRCAm coexisting with microsatellite instability are likely bystander events that may not result in sensitivity to poly (ADP-ribose) polymerase inhibitors.
No takes yet. Share an insight, caveat, or question.
Sokol et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: